BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol 2013; 19(47): 8887-8894 [PMID: 24379612 DOI: 10.3748/wjg.v19.i47.8887] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108. [PMID: 25651787 DOI: 10.3322/caac.21262] [Cited by in Crossref: 16506] [Cited by in F6Publishing: 17144] [Article Influence: 2358.0] [Reference Citation Analysis]
2 Dong H, Zhang L, Qian Z, Zhu X, Zhu G, Chen Y, Xie X, Ye Q, Zang J, Ren Z, Ji Q. Identification of HBV-MLL4 Integration and Its Molecular Basis in Chinese Hepatocellular Carcinoma. PLoS One. 2015;10:e0123175. [PMID: 25901726 DOI: 10.1371/journal.pone.0123175] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
3 Golabi P, Jeffers T, Younoszai Z, Otgonsuren M, Sayiner M, Mishra A, Venkatesan C, Younossi ZM. Independent Predictors of Mortality and Resource Utilization in Viral Hepatitis Related Hepatocellular Carcinoma. Ann Hepatol 2017;16:555-64. [PMID: 28611258 DOI: 10.5604/01.3001.0010.0290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
4 Deng L, Yang J, Chen H, Ma B, Pan K, Su C, Xu F, Zhang J. Knockdown of TMEM16A suppressed MAPK and inhibited cell proliferation and migration in hepatocellular carcinoma. Onco Targets Ther 2016;9:325-33. [PMID: 26834491 DOI: 10.2147/OTT.S95985] [Cited by in Crossref: 9] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
5 zur Hausen H, de Villiers EM. Cancer "causation" by infections--individual contributions and synergistic networks. Semin Oncol 2014;41:860-75. [PMID: 25499643 DOI: 10.1053/j.seminoncol.2014.10.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
6 Guo W, Tan W, Liu S, Huang X, Lin J, Liang R, Su L, Su Q, Wang C. MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. Tumour Biol 2015;36:9049-57. [PMID: 26084609 DOI: 10.1007/s13277-015-3644-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
7 Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021; 27(17): 2025-2038 [PMID: 34007137 DOI: 10.3748/wjg.v27.i17.2025] [Reference Citation Analysis]
8 Zur Hausen H, de Villiers EM. Reprint of: cancer "causation" by infections--individual contributions and synergistic networks. Semin Oncol 2015;42:207-22. [PMID: 25843727 DOI: 10.1053/j.seminoncol.2015.02.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
9 Hou KZ, Fu ZQ, Gong H. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. World J Gastroenterol 2015; 21(2): 475-483 [PMID: 25593462 DOI: 10.3748/wjg.v21.i2.475] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
10 Dillman RO. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum Vaccin Immunother 2017;13:528-32. [PMID: 27808593 DOI: 10.1080/21645515.2016.1244149] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
11 Wang Z, Li F, Quan Y, Shen J. Avicularin ameliorates human hepatocellular carcinoma via the regulation of NF‑κB/COX‑2/PPAR‑γ activities. Mol Med Rep 2019;19:5417-23. [PMID: 31059053 DOI: 10.3892/mmr.2019.10198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
12 Lin Y, Liu S, Su L, Su Q, Lin J, Huang X, Wang C. miR-570 Inhibits Proliferation, Angiogenesis, and Immune Escape of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2018;33:252-7. [PMID: 29874097 DOI: 10.1089/cbr.2017.2389] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
13 Deng X, Cheng J, Zhan N, Chen J, Zhan Y, Ni Y, Liao C. MicroRNA-135a expression is upregulated in hepatocellular carcinoma and targets long non-coding RNA TONSL-AS1 to suppress cell proliferation. Oncol Lett 2021;22:808. [PMID: 34630715 DOI: 10.3892/ol.2021.13069] [Reference Citation Analysis]
14 Rong W, Zhang Y, Yang L, Feng L, Wei B, Wu F, Wang L, Gao Y, Cheng S, Wu J, Xiao T. Post-surgical resection prognostic value of combined OPN, MMP7, and PSG9 plasma biomarkers in hepatocellular carcinoma. Front Med 2019;13:250-8. [PMID: 29770948 DOI: 10.1007/s11684-018-0632-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Seto W, Yuen M. Hepatitis B Virus: Asian Perspective. In: Wong RJ, Gish RG, editors. Clinical Epidemiology of Chronic Liver Diseases. Cham: Springer International Publishing; 2019. pp. 99-116. [DOI: 10.1007/978-3-319-94355-8_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Lu G, Villa JA, Donlin MJ, Edwards TC, Cheng X, Heier RF, Meyers MJ, Tavis JE. Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors. Antiviral Res 2016;135:24-30. [PMID: 27693161 DOI: 10.1016/j.antiviral.2016.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
17 Wu Q, Chen X, Wang P, Wu Q, Qi X, Han X, Chen L, Meng X, Xu K. Delivery of Arsenic Trioxide by Multifunction Nanoparticles To Improve the Treatment of Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2020;12:8016-29. [PMID: 31997633 DOI: 10.1021/acsami.9b22802] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Huang QT, Huang Q, Zhong M, Wei SS, Luo W, Li F, Yu YH. Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies. J Viral Hepat 2015;22:1033-42. [PMID: 26081198 DOI: 10.1111/jvh.12430] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
19 Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 15.5] [Reference Citation Analysis]
20 Cho HJ, Kim SS, Ahn SJ, Park SY, Park JH, Kim JK, Wang HJ, Cheong JY, Cho SW. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment. Cytokine. 2015;73:245-252. [PMID: 25797190 DOI: 10.1016/j.cyto.2015.02.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
21 Cho HJ, Kim SS, Nam JS, Oh MJ, Kang DR, Kim JK, Lee JH, Kim B, Yang MJ, Hwang JC, Lim SG, Shin SJ, Lee KM, Yoo BM, Lee KJ, Cho SW, Cheong JY. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib. Cytokine 2017;95:118-25. [PMID: 28260649 DOI: 10.1016/j.cyto.2017.02.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
22 Dai M, Yang YW, Guo WH, Wang FL, Xiao GM, Li YM, Yang HZ. Addition and Subtraction Theory of TCM Using Xiao-Chaihu-Decoction and Naturopathy in Predicting Survival Outcomes of Primary Liver Cancer Patients: A Prospective Cohort Study. Evid Based Complement Alternat Med 2016;2016:4723530. [PMID: 27843477 DOI: 10.1155/2016/4723530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 Simão A. Hepatocellular Carcinoma: Portuguese Data in Chronic Hepatitis B Patients on Antiviral Therapy and Treatment Results With Sorafenib. GE Port J Gastroenterol 2016;23:231-2. [PMID: 28868467 DOI: 10.1016/j.jpge.2016.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
24 Abraham JA, Golubnitschaja O. Time for paradigm change in management of hepatocellular carcinoma: is a personalized approach on the horizon? Per Med 2016;13:455-67. [PMID: 29767598 DOI: 10.2217/pme-2016-0013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]